Rua Santos Dumont, 182,
4o andar, 88015-020,
Centro, Florianópolis-SC
Tel: (48) 3003-9855
Formação e Treinamento
Faculdade de Medicina - Universidade Federal Da Bahia (2002 - 2008)
Residência de Clínica Médica - Hospital das Clínicas da Universidade Federal do Rio Grande do Sul (2009-2011)
Residência de Oncologia Clínica - AC Camargo Cancer Center (2011 - 2014)
Mestrado em Ciências da Saúde - AC Camargo Cancer Center (2019)
Doutorado em Ciências da Saúde - AC Camargo Cancer Center (em andamento)
Experiência
Oncologista titular - AC Camargo Cancer Center (2014 - 2022)
Co-diretor do Centro de Referência de Tumores do Aparelho Digestivo Alto - AC Camargo Cancer Canter (2019 - 2022)
Oncologista titular - Grupo Oncoclínicas Florianópolis (2022 - )
Oncologista titular - Centro de Pesquisas Oncológicas - CEPON (2022 - )
Coordenador do Departamento de Oncologia Clínica - Centro de Pesquisas Oncológicas - CEPON (2024 - )
Experiência Internacional
Estágio em Oncologia Clínica - Allegheny General Hospital, Pittsburgh, PA-EUA
Estágio em Oncologia Clínica - Istituto Nazionale dei Tumori, Milão-ITA
Estágio em Neoplasias Peritoneais - Kishiwada General Hospital, Kishiwada-JAP
Cursos
Revisão Sistemática e Meta-Análise - University College of London (2018)
Matemática Estatística - Harvard University (2019)
Participações em Entidades Médicas
Membro da Sociedade Americana de Oncologia Clínica (ASCO)
Membro da Sociedade Européia de Oncologia Médica (ESMO)
Membro da Sociedade Brasileira de Oncologia Clínica (SBOC)
Membro do Comitê Científico do Grupo de Tumores Gastrointestinais da Sociedade Brasileira de Oncologia Clínica (SBOC)
Membro Diretor do Grupo Brasileiro de Tumores Gastrointestinais (GTG)
Membro do Comitê Diretivo do Grupo de Tumores Gastrointestinais do Grupo Cooperativo de Oncologia Latinoamericano (LACOG)
Publicações Científicas
1. de Jesus VHF, Ribeiro TN, LTD Chinen, et al. Epidemiological Profile and Treatment Outcomes in Young Adults (19-29 Years of Age) Treated for Cancer in a Tertiary Hospital in São Paulo, Brazil. J Adolesc Young Adult Oncol 2017; 6(2): 333-340. PubMed
2. de Jesus VHF, Camandaroba MPG, Donadio MDS, et al. Clinico‐pathological features and survival of patients with malignant exocrine pancreatic neoplasms: The AC Camargo Cancer Center experience. J Surg Oncol 2019; 119(1): 71-78. PubMed
3. de Jesus VHF, Camandaroba MPG, Donadio MDS, et al. Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX. J Gastrointest Oncol 2018; 9(5): 806-819. PubMed
4. Fava BEC, da Costa Jr WL, Medeiros MLL,..., de Jesus VHF, et al. Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center. World J Surg Oncol 2019; 16(1): 62. PubMed
5. de Jesus VHF, Felismino TC, Silva MJB, et al. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies. Clinics 2018; 73 (suppl 1): e510s. PubMed
6. de Jesus VHF, da Costa Jr WL, Marques TMDM, et al. Role of staging laparoscopy in the management of Pancreatic Duct Carcinoma (PDAC): Single-center experience from a tertiary hospital in Brazil. J Surg Oncol 2017; 117(5): 819-828. PubMed
7. de Jesus VHF, Camandaroba MPG, Donadio MDS, et al. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. J Gastrointest Oncol 2018; 9(4): 694-707. PubMed
8. Paiva Jr TF, de Jesus VHF, Marques RA, et al. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer 2015; 15: 643. PubMed
9. Nicolau UR, de Jesus VHF, Lima ENP, et al. Early metabolic 18F-FDG PET/CT response of locally advanced squamous-cell carcinoma of head and neck to induction chemotherapy: A prospective pilot study. PLoS One 2018; 13(8): e0200823. PubMed
10. da Costa AABA, Costa FD, Araújo DV, ..., de Jesus VHF, et al. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. Med Oncol 2018; 36(1): 8. PubMed
11. de Jesus VHF, Dettino ALA. Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI). J Hepatocell Carcinoma 2018; 5: 87-90. PubMed
12. Marques MC, Ribeiro HSC, da Costa Jr WL, de Jesus VHF, et al. Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)? J Surg Oncol 2018; 117(5): 858-863. PubMed
13. Abdallah EA, Braun AC, Flores BCTCP, ..., de Jesus VHF, et al. The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer. Oncologist 2019; 24(9): e854-e863. PubMed
14. Coimbra FJF, de Jesus VHF, Franco CP, et al. Predicting overall and major postoperative morbidity in gastric cancer patients. J Surg Oncol 2019; 120(8): 1371-1378. PubMed
15. Costa GC, de Jesus VHF, Camandaroba MPG, et al. Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience. Ther Adv Med Oncol 2019; 11: 1758835919874650. PubMed
16. Felismino TC, de Oliveira ACF, Alves ACF, ..., de Jesus VHF, et al. Primary Tumor Location Is a Predictor of Poor Prognosis in Patients with Locally Advanced Esophagogastric Cancer Treated with Perioperative Chemotherapy. j Gastrointest Cancer 2020; 51(2): 484-490. PubMed
17. Coimbra FJF, de Jesus VHF, Ribeiro HSC, et al. Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery. Ann Surg Oncol 2019; 26(11): 3618-3626. PubMed
18. Muniz TP, de Jesus VHF, Souza VAR, et al. A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases. J Thorac Dis 2019; 11(9): 3909-3919. PubMed
19. de Jesus VHF, da Costa Jr WL, Felismino TC, et al. Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method. J Gastrointest Oncol 2019; 10(6): 1110-1119. PubMed
20. Torres SM, da Silva DGV, Ribeiro HSC, ..., de Jesus VHF, et al. Short‐term outcomes after vascular resection for pancreatic tumors: Lessons learned from 72 cases from a single Brazilian Cancer Center. J Surg Oncol 2020; 121(5): 857-862. PubMed
21. Camandaroba MPG, Iseas S, Oliveira C, ..., de Jesus VHF, et al. Disease-Free Survival and Time to Complete Response After Definitive Chemoradiotherapy for Squamous-Cell Carcinoma of the Anus According to HIV Infection. Clin Colorectal Cancer 2020; 19(3) :e129-e136. PubMed
21. Coimbra FJF, Torres OJM, Alikhanov R, ..., de Jesus VHF, et al. Consenso Brasileiro de Carcinoma Incidental de Vesícula Biliar. ABCD Arq Bras Cir Dig 2020; 33(1): e1496. SciELO
22. Felismino TC, de Jesus VHF, Uchóa Jr BCM, et al. Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis. Ecancermedicalscience 2020; 14: 1014. PubMed
23. Mauro C, de Jesus VHF, Barros M, et al. Opportunistic and serious infections in patients with neuroendocrine tumors treated with everolimus: a multicenter study of real-world patients. Neuroendocrinology 2021; 111(7): 631-638. PubMed
24. Peixoto RD, Rocha-Filho DR, Weschenfelder RF, ..., de Jesus VHF, et al. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience 2020; 14: 1126. PubMed
25. Bartelli TF, de Abrantes LLS, Freitas HC, ..., de Jesus VHF, et al. Genomics and epidemiology for gastric adenocarcinomas (GE4GAC): a Brazilian initiative to study gastric cancer. App Cancer Res 2019; 39: 12. BVS
26. de Jesus VHF, Camandaroba MPG, Calsavara VF, et al. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. Ther Adv Med Oncol 2020; 12: 1758835920905408. PubMed
27. de Almeida MJ, de Mello CAL, Camandaroba MPG, de Jesus VHF. Fluoropyrimidine-based maintenance chemotherapy after FOLFIRINOX for patients with metastatic pancreatic adenocarcinoma: a retrospective analysis. Ann Pancreat Cancer 2020; 3: 13. Ann Pancreat Cancer
28. Diniz TP, da Costa Jr WL, de Jesus VHF, et al. Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity-score matched analysis. J Surg Oncol 2020; 121(5): 823-832. PubMed
29. de Jesus VHF, Riechelmann RP. Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis. Ecancermedicalscience 2021; 15: 1276. PubMed
30. de Oliveira TB, Braun AC, Nicolau UR, ..., de Jesus VHF, et al. Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma. Oral Oncol 2021; 121: 105480. PubMed
31. Donadio MDS, Oliveira ACF, Moura LL, de Jesus VHF, et al. Real-world data suggest that geriatric assessment fails to stratify risk in treating older adults with lung cancer. Bras J Oncol 2021; 17: :e-20210030. BJO
32. de Jesus VHF, da Costa Jr WL, Claro LCL, et al. Disparities in access to health care system as determinant of survival for patients with pancreatic cancer in the State of São Paulo, Brazil. Sci Rep 2021; 11(1): 6346. PubMed
33. Diniz TP, da Costa Jr WL, Gomes CC, de Jesus VHF, et al. Symptomatic Recurrence and Survival Outcomes After Curative Treatment of Gastric Cancer: Does Intensive Follow-up Evaluation Improve Survival? Ann Surg Oncol 2022; 29(1): 274-284. PubMed
34. Donadio MDS, de Jesus VHF, Barros MJ. Using chemotherapy against metastatic pancreatic neuroendocrine neoplasm: how aggressively do we treat it? Real world data from a Brazilian Cancer Center. Bras J Oncol 2022; 18: e-20220285. BJO
35. Gonzales BA, Diniz AL, Torres ML, ..., de Jesus VHF. Patterns of disease relapse and posttreatment follow-up of patients with resected pancreatic adenocarcinoma: A single-center analysis. J Surg Oncol 2022; 126(4): 708-717. PubMed
36. Taboada R, Claro L, Felismino T, ..., de Jesus VH, et al. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms. J Neuroendocrinol 2022; 34(4): e13099. PubMed
37. Mathias-Machado MC, de Jesus VHF, Oliveira LJC, et al. Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications. Cancers 2023; 14(21): 5330. PubMed
38. Ribeiro HSC, Menezes JN, da Costa jr WL, de Jesus VHF, et al. PD-L1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy. J Surg Oncol 2022; 126(1): 150-160. PubMed
39. de Almeida MJ, Camandaroba MPG, Nassar Jr AP, de Jesus VHF. Short-term survival of patients with advanced pancreatic cancer admitted to intensive care unit: a retrospective cohort study. Ecancermedicalscience 2022; 16: 1475. PubMed
40. Felismino TC, Oliveira FMA, Fogassa CAZ, ..., de Jesus VHF, et al. Evaluation of prognostic factors in patients undergoing first-line chemotherapy for advanced biliary tract cancer: a retrospective analysis from a South American cancer centre. Ecancermedicalscience 2022; 16: 1345. PubMed
41. Silva JR, Riechelmann RSP, Vizzacchi BA, ..., de Jesus VHF, et al. Clinical outcomes of patients with pancreatic tumors discussed in tumor board. Rev Col Bras Cir 2022; 49: e20223150. SciELO
42. Rocha-Filho DR, Peixoto RD, Weschelfelder RF, ..., de Jesus VHF, et al. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021; 15: 1195. PubMed
43. Riechelmann RP, Donadio MDS, de Jesus VHF, et al. Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms. End Relat Cancer 2023; 30(6): e220258. PubMed
44. de Brito ABC, Riechelmann RP, de Jesus VHF. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocarcinoma (MPA) During First-Line Treatment With FOLFIRINOX: A Single-Center Retrospective Analysis. Cancer Control 2023; 30: 10732748221149543. PubMed
45. Kinker GS, Vitiello GAF, Diniz AB,, ..., de Jesus VHF, et al. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas. Gut 2023; 72(10): 1927-1941. PubMed
46. de Jesus VHF, Riechelmann RP. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s Perspective. Cancer Control 2023; 30: 10732748231173212. PubMed
47. Riechelmann RP, Taboada RG, de Jesus VHF, et al. Therapy Sequencing in Patients With Advanced Neuroendocrine Neoplasms. Am Soc Clin Oncol Educ Book 2023; 43: e389278. PubMed
48. Barros MJ, Strosberg J, Al-Toubah T, de Jesus VHF, et al. HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors. Ther Adv Med Oncol 2023; 15: 17588359231186041. PubMed
49. de Jesus VHF, Machado-Mathias MC, de Farias JPF, et al. Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure. Cancers 2023; 15(20): 5015. PubMed
50. de Jesus VHF, Peixoto RD, Ribeiro HSC, et al. Current clinical practice in the management of Brazilian patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC). J Surg Oncol 2023; online ahead of print. PubMed
51. Mathias-Machado MC, de Jesus VHF, Jacome A, et al. Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know? Cancers 2024; 16(3): 679. PubMed
52. Azeredo-da-Silva ALF, de Jesus VHF, Agirrezabal I, et al. Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta- Analysis. Adv Ther 2024; 41(4): 1606-1620. PubMed
Diretrizes e Guidelines
Diretrizes de Tratamento da Sociedade Brasileira de Oncologia Clínica
Câncer de Pâncreas (2019, 2020, 2021, 2022)
Diretrizes de Tratamento da Sociedade Brasileira de Oncologia Clínica
Câncer Colorretal (2023, 2024)
Diretrizes de Tratamento da Sociedade Brasileira de Oncologia Clínica
Câncer Anal (2023, 2024)
Participações em Congressos
Congresso da Sociedade Brasileira de Oncologia Clínica (SBOC) 2023 - Palestrante
Adenocarcinoma de pâncreas localmente avançado: Quimioterapia neoadjuvante?
Congresso da Sociedade Brasileira de Cirurgia Oncológica (SBCO) 2023 - Palestrante
Colangiocarcinoma Intra-hepático cN+ / Nódulo satélite - qual a melhor abordagem inicial?
Congresso da Sociedade Brasileira de Cirurgia 2023 - Palestrante
Pâncreas - O papel da neoadjuvância em 2023
Congresso da Sociedade Brasileira de Radiologia Intervencionista (SOBRICE) 2022 - Palestrante
SIRT vs Systemic treatment in advanced HCC, is there a competition?
Congresso da Sociedade Brasileira de Radiologia Intervencionista (SOBRICE) 2022 - Palestrante
TARE in colorectal metastases, what is the oncologist's perspective?
Congresso da Sociedade Brasileira de Oncologia Clínica (SBOC) 2022 - Palestrante
Neoadjuvância para adenocarcinoma de pâncreas: Quando indicar?
Congresso da Sociedade Brasileira de Cirurgia Oncológica (SBCO) 2021 - Palestrante
Existe papel da terapia neoadjuvante nos tumores de vesícula biliar e de vias biliares?
Congresso da Sociedade Brasileira de Oncologia Clínica (SBOC) 2021 - Palestrante
Tratamento perioperatório no câncer gástrico T2N0? Sim
Congresso da Sociedade Brasileira de Radiologia Intervencionista (SOBRICE) 2020 - Palestrante
Hepatocellular Carcinoma: Combining Locorregional Treatment with Systemic Therapy in 2020
Congresso da Sociedade Brasileira de Oncologia Clínica (SBOC) 2019 - Palestrante
Opções para o sequenciamento no tratamento de câncer de pâncreas
Participações em Corpo Editorial de Revistas
Brazilian Journal of Oncology (2019 - 2021)
Therapeutic Advanced in Medical Oncology (2024 - )
Capítulos de Livros Publicados
1. de Jesus VHF, de Lima VCC, Silva ILAF, et al. Neutropenia Febril. Em: Prevenção e Tratamento de Infecções Oportunísticas em Pacientes Onco-hematológicos e Transplante de Células-tronco Hematoloéticas. Primeira Edição. São Paulo: Lemar, p. 39-53.
2. Mathias CMC, Munhoz R, de Jesus VHF. Princípios de Tratamento Sistêmico. Em: Tratado Brasileiro de Cirugia Oncológica (SBCO). Primeira Edição. Rio de Janeiro: Rubio, p 17-19.
3. Boff MF, de Jesus VHF, Cavalho ALL, et al. Tumores Sólidos do Pâncreas. Em: Tratado Brasileiro de Cirugia Oncológica (SBCO). Primeira Edição. Rio de Janeiro: Rubio, p 441-445.
4. Diniz AL, de Godoy AL, Cury Filho AMC, ..., de Jesus VHF, et al. Cirurgia Abdominal. Em: Manual de Condutas Diagnósticas e Terapêuticas em Oncologia (AC Camargo Cancer Center). Quarta Edição. São Paulo: Âmbito, p 67-92.
5. da Costa CML, Estrada DA, Pinto FFE,..., de Jesus VHF, et al. Ortopedia. Em: Manual de Condutas Diagnósticas e Terapêuticas em Oncologia (AC Camargo Cancer Center). Quarta Edição. São Paulo: Âmbito, p 95-110.
Atividades Docentes
Preceptor da Residência de Oncologia Clínica - AC Camargo Cancer Center
(2014 - 2022)
Preceptor da Residência de Oncologia Clínica - Centro de Pesquisas Oncológicas - CEPON (2022 - )
Professor Convidado da Pós-Graduação em Cardio-Oncologia da Galen Academy (2024 - )
Prêmios
Prêmio Celestino Bourroul - Residente Homenageado - AC Camargo Cancer Center (2013)
Prêmio de Melhor Trabalho de Conclusão de Curso do Departamento de Oncologia Clínica - AC Camargo Cancer Center (2013)
Prêmio de Pesquisador Homenageado - AC Camargo Cancer Center (2020)
